Texas Administrative Code
Title 22 - EXAMINING BOARDS
Part 9 - TEXAS MEDICAL BOARD
Chapter 198 - STANDARDS FOR USE OF INVESTIGATIONAL AGENTS
Subchapter A - STANDARDS FOR USE OF INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS, OR DEVICES
Section 198.1 - Purpose

Universal Citation: 22 TX Admin Code ยง 198.1

Current through Reg. 49, No. 38; September 20, 2024

(a) The purpose of this chapter is to recognize that physicians should be allowed a reasonable and responsible degree of latitude in the kinds of therapies they offer their patients. The Board has determined that use of investigational agents constitutes the practice of medicine and is thus subject to all applicable statutory and regulatory provisions of the Medical Practice Act and Board Rules unless otherwise specifically stated. Section 198.4 of this chapter (relating to Use of Investigational Drugs, Biological Products, or Devicesfor Patients with Terminal Illnesses) sets forth specific requirements applicable only to terminal patients being treated with investigational drugs, biological products or devices.

(b) Subchapter B of this title (relating to Investigational Stem Cell Treatments for Patients with Certain Severe Chronic Diseases or Terminal Illnesses) sets forth separate requirements applicable only to the use of investigational stem cell treatments.

Disclaimer: These regulations may not be the most recent version. Texas may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.